Abstract: An end fitting capable of being fitted to the body of a manual or automated device for sampling a biological substance of microbial origin, including: a) a distal end including a means for sampling the biological substance of microbial origin, b) a proximal free end intended to come into contact with the body of the sampling device and to enable the attachment of the end fitting to said body, the end fitting being characterized in that all or some of the free distal end consists of a fibrous material having a porosity at least equal to 30%.

Abstract: A method for characterizing at least one microorganism from a sample includes identifying the at least one microorganism and determining the properties of typing, potential resistance to at least one antimicrobial, and virulence factor. The properties of typing, resistance to at least one antimicrobial, and virulence factor for the at least one microorganism are determined by implementing mass spectrometry using proteins, peptides and/or metabolites as markers of the properties of typing, resistance to at least one antimicrobial, and virulence factor.

Abstract: The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Leukocyte Elastase Inhibitor tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumor marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

Abstract: The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

Abstract: The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the protein disulfide isomerase tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-PDI monoclonal antibody directed against a PDI epitope chosen from the epitopes of sequence SEQ ID NO: 1, SEQ ID NO: 2 with an aromatic amino acid having a three-dimensional structure similar to that of PDI, and SEQ ID NO: 3.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4+SEQ ID No. 5, SEQ ID No. 6+SEQ ID No. 7 and SEQ ID No. 8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: The present invention relates to a method for characterizing at least one microorganism from a sample, said method including identifying said at least one microorganism and determining the properties of typing, potential resistance to at least one antimicrobial, and virulence factor, characterized in that determining the properties of typing, resistance to at least one antimicrobial, and virulence factor for said at least one microorganism is implemented by means of mass spectrometry through the use of proteins, peptides and/or metabolites as markers of said properties of typing, resistance to at least one antimicrobial, and virulence factor.

Abstract: The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the protein disulfide isomerase tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-PDI monoclonal antibody directed against a PDI epitope chosen from the epitopes of sequence SEQ ID NO: 1, SEQ ID NO: 2 with an aromatic amino acid having a three-dimensional structure similar to that of PDI, and SEQ ID NO: 3.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Abstract: The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Leukocyte Elastase Inhibitor tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.